Business Overview - Cheech & Chong built a $100 million cannabis empire [1] Industry Impact - The article highlights how Cheech & Chong successfully transitioned their legacy into a lucrative cannabis business [1]

Core Insights - The article discusses the performance of active U.S. small-cap managers, highlighting their strong long-term performance relative to the Russell 2000 index, particularly during value stock-led periods [2][3][4] Small-Cap Management Performance - Active small-cap managers outperformed the Russell 2000 index 58% of the time over rolling 5-year periods, with an 82% success rate during value-led periods and only 15% during growth-led periods [3] - 65% of the analyzed periods were value-led, indicating a favorable environment for active management [3] - When the Russell 2000's annualized 5-year return was 5% or lower, value stocks outperformed growth stocks only 48% of the time, but they averaged higher returns [4] - In periods with annualized 5-year returns between 5-10%, value stocks exceeded growth stocks 70% of the time, relevant as small-cap returns are expected to be in this range over the next five years [4] Hedge Fund Interest in Penny Stocks - The article lists the 12 best NASDAQ penny stocks to buy according to hedge funds, emphasizing the strategy of imitating top hedge fund picks to outperform the market [5][9] - The methodology involved shortlisting the largest companies trading under $5 on the NASDAQ and ranking them by the number of hedge fund holders [7][8] Company Highlights - **Prospect Capital Corporation (NASDAQ:PSEC)**: - Price as of September 12: $2.79, with 11 hedge fund holders [10] - Recently completed an $18 million investment in The Ridge, a physician-led addiction treatment facility [10][11] - The company has a net debt to total assets ratio of 30.4%, indicating high leverage, and is strategically exiting a real estate investment yielding 4.5% [13][14] - **Tilray Brands, Inc. (NASDAQ:TLRY)**: - Price as of September 12: $1.12, with 12 hedge fund holders [15] - Recently partnered with the Denver Broncos to launch a new lineup of spirits, celebrating their ongoing collaboration [15][16] - Analyst Kaumil Gajrawala raised the price target from $1.50 to $2, maintaining a Buy rating, influenced by the rescheduling of cannabis regulations in the U.S. [19][20]

Core Insights - The U.S. cannabis industry is rapidly maturing with larger markets and more efficient operators, despite ongoing federal restrictions on full legalization [1] - Federal policy changes are gradually occurring, indicating a potential long-term shift in the cannabis landscape [2] - State-level leaders are crucial for monitoring growth and investment opportunities in the cannabis sector [1][23] Federal Legalization Efforts - Cannabis remains illegal federally, but the Department of Justice is considering rescheduling it from Schedule I to Schedule III, which would acknowledge its medical use and lower abuse risk classification [2] - This rescheduling would not legalize recreational use but would ease research restrictions and reduce tax burdens under Section 280E [2] Banking Reform - The SAFER Banking Act aims to normalize banking for cannabis businesses, reducing cash usage and improving transparency [4] - This reform would provide legal protection for banks, allowing more institutions to serve the cannabis industry, thus lowering costs and enhancing capital access for operators [4] Growth Projections - Cannabis sales are projected to reach approximately $31.4 billion in 2024, with steady double-digit growth expected into 2025 [5] - By 2030, total sales are anticipated to exceed $67 billion, with some estimates reaching nearly $87 billion by 2035, contingent on expanded legalization and consumer shifts from the illicit market [5] State-Level Success Stories - **Michigan**: Market surpassed $3 billion in 2024, with strong demand despite falling prices due to competition [6] - **Missouri**: Sales reached $1.46 billion in 2024, driven by streamlined licensing and moderate taxes [7] - **Illinois**: Sales exceeded $2 billion in 2024, with tax revenues over $490 million, supported by social equity programs and strong urban demand [8] - **New Jersey**: Revenues surpassed $2 billion, benefiting from early access for medical operators [9] - **Florida**: Medical-only market with nearly 900,000 registered patients, showing significant sales potential [10] - **New York**: Sales on track to reach the billion-dollar mark, with improving licensing and supply chains [11] Tax Revenues and Community Impact - Since 2014, adult-use states have collected nearly $25 billion in tax revenue, supporting education, public health, and social equity initiatives [12] - Legal markets reduce illicit activity and provide consumers with tested and labeled products, benefiting communities through job creation and reinvestment [12] Future Considerations - Federal rescheduling and the SAFER Banking Act could significantly improve industry fundamentals [13] - State ballot measures and legislative sessions will influence growth trajectories, with tax debates being crucial for margins and expansion [13] Leading Companies - **Trulieve Cannabis Corp.**: Dominates Florida's medical market with over 190 dispensaries, reporting billions in annual revenue [15] - **Curaleaf Holdings Inc.**: Operates over 150 dispensaries across high-growth states, with strong revenue growth exceeding a billion dollars [17] - **Green Thumb Industries Inc.**: Operates more than 90 dispensaries, known for strong consumer brands and solid revenues above $1 billion annually [19][20] Investor Considerations - Investors should focus on efficient operators, evaluate tax structures, and consider municipal support [22] - Strong brands with consistent quality are likely to gain market share, and balance sheets will be critical post-280E reform [22]

WATCH: How Cheech & Chong Turned Their Legacy Into A $100 Million Cannabis Empire https://t.co/n7JN1oE9O4 https://t.co/LIBk9885Zl ...

Industry Overview - The U.S. cannabis industry is experiencing significant growth, with legal sales surpassing $33 billion in 2024 and projected revenues of $50 billion by 2030 [1][3] - Expansion into new adult-use markets and growth in medical programs are creating new opportunities [1][3] - Federal rescheduling and potential banking reforms are increasing optimism in the sector [1][2] Key Companies - Trulieve Cannabis Corp. operates 231 retail dispensaries and has a strong presence in Florida, with a cultivation and processing footprint of over four million square feet [4][7] - Curaleaf Holdings, Inc. operates in 19 states with 154 retail dispensaries and has recently consolidated its international business, enhancing its global position [8][10] - Green Thumb Industries, Inc. operates over 101 retail locations and 20 manufacturing facilities, focusing on both adult-use and medical markets [12][14] Financial Performance - Trulieve reported $302 million in revenue for Q2 2025, with a gross margin of 61% and adjusted EBITDA of $111 million [7][15] - Curaleaf's Q2 2025 net revenue was $314.5 million, an 8% decline from the previous year, with a gross margin of 49% [10][11] - Green Thumb Industries reported Q2 2025 revenue of $293.3 million, a 4.7% increase year-over-year, with a gross margin of 49.9% [14][15] Market Positioning - Trulieve is recognized for its retail penetration and product distribution, supported by a large loyalty program with over 725,000 members [4][7] - Curaleaf's extensive retail and wholesale network positions it well for continued expansion, despite recent revenue challenges [8][11] - Green Thumb's strategy combines brand development with an expanding retail footprint, contributing to steady sales growth [12][14] Investment Considerations - The cannabis sector remains volatile, necessitating careful technical analysis and disciplined risk management for traders [1][2] - Companies with strong fundamentals and expanding footprints are likely to benefit from ongoing industry developments [2][15] - Investors are advised to monitor technical setups while applying risk management strategies to navigate the market effectively [16]

Group 1 - Alan Brochstein is a pioneer in the cannabis investment sector, having focused exclusively on this industry since 2007 [1] - He founded AB Analytical Services to provide independent consulting to registered investment advisors [1] - Brochstein is the managing partner of New Cannabis Ventures, which has been a key provider of financial information in the cannabis industry since 2015 [1] Group 2 - Alan has led the investing group 420 Investor since 2013, which focuses on publicly-traded cannabis stocks [2] - The group covers 20 stocks, providing investment news, earnings report previews, and post-report analyses [2] - Additional features of the group include a model portfolio, 10 weekly videos with chart analysis, 3 weekly summary pieces, a monthly newsletter, and a chat for questions [2]

Group 1 - Xebra Brands Ltd. is an international cannabis company [1] - The company announced a consolidation of its issued and outstanding share capital [1] - The consolidation will be on the basis of one post-consolidation common share for each ten pre-consolidation common shares [1] - The effective date for the consolidation is September 19, 2025 [1]

Core Insights - AYR Wellness Inc. has filed its unaudited interim condensed consolidated financial statements for Q1 2025, ending March 31, 2025 [1] - The financial statements and Management's Discussion and Analysis (MD&A) are available for review on SEDAR+ and the SEC's EDGAR system [2] - Shareholders and interested parties are encouraged to review the filed materials for comprehensive information regarding the Company's operating performance and liquidity position [3] Non-GAAP Measures - The Company reports non-GAAP measures to evaluate business performance and manage capital structure, which may not be comparable to similar measures from other issuers [4] - Non-GAAP measures such as "Adjusted EBITDA" and "Adjusted Gross Profit" are provided to complement GAAP measures and offer further understanding of operational results [5][6] - Adjusted EBITDA is defined as income from continuing operations before interest and taxes, adjusted for non-core costs and non-cash items [7] - Adjusted Gross Profit represents gross profit adjusted for certain costs, including interest and depreciation, with reconciliations provided in the MD&A [8] Company Overview - AYR Wellness is a vertically integrated U.S. multi-state cannabis operator with over 90 licensed dispensaries and a portfolio of cannabis CPG brands [11] - The Company aims to deliver high-quality cannabis products while positively impacting its team members and the communities it serves [11]

Industry Focus Shift - Tilray, once a prominent cannabis company, is now heavily invested in the beer industry [1] Business Strategy - The company's strategic shift involves expanding beyond cannabis into the alcoholic beverage market [1]

WATCH: How Cheech & Chong Turned Their Legacy Into A $100 Million Cannabis Empire https://t.co/l038cafphz https://t.co/QHrusQyAtV ...